Rising surgeries and dialysis drive demand, while LMWH, prefilled syringes, biosynthetic and bovine sources, and localized Asian production offer key opportunities.
Heparin Market Global Heparin Market Growth Rate By Region
Dublin, Aug. 21, 2026 (GLOBE NEWSWIRE) — The “Heparin – Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)” has been added to ResearchAndMarkets.com’s offering.
Global Heparin Market to Reach USD 15.27 Billion by 2031 as Surgical and Dialysis Demand Rises
The global heparin market is projected to grow from USD 10.04 billion in 2025 to USD 10.73 billion in 2026 before reaching USD 15.27 billion by 2031. The market is expected to register a compound annual growth rate of 7.31% from 2026 to 2031, supported by increasing surgical procedure volumes, rising dialysis demand, an aging population, and continued adoption of low-molecular-weight heparin.
Growth in Surgical Procedures and Dialysis Supports Heparin Demand
Cardiovascular and orthopedic procedure volumes continue to increase worldwide, sustaining demand for anticoagulation in surgical and postoperative settings. The growing prevalence of end-stage renal disease is also increasing the number of dialysis procedures, where anticoagulation remains an important component of treatment.
Clinical advances are improving anticoagulation options for patients with elevated bleeding risks. Recent studies involving heparin-coated dialyzers and intermittent saline flushing reported the elimination of clotting events in selected high-risk patients. Although regional anticoagulation and heparin-free dialysis techniques are becoming available for certain cases, the overall expansion of dialysis services is expected to maintain heparin consumption through the forecast period.
Low-Molecular-Weight Heparin Leads Product Demand
Low-molecular-weight heparin accounted for 63.1% of global market revenue in 2025. Its predictable pharmacokinetic profile, reduced monitoring requirements, and suitability for once-daily dosing continue to encourage adoption in outpatient care, surgical prophylaxis, and oncology settings. Manufacturers are also expanding pre-filled syringe offerings to improve dosing convenience and support safer bedside administration.
Synthetic and biosynthetic heparin is forecast to be the fastest-growing product category, advancing at a CAGR of 8.40%. Investment in microbial and chemo-enzymatic production pathways is accelerating as the industry seeks alternatives to animal-derived raw materials. In 2025, the National Heart, Lung, and Blood Institute funded a USD 306,656 U.S. project focused on scaling microbial heparin production, highlighting growing interest in non-animal sources.
Supply-Chain Resilience Remains a Strategic Priority
Animal-derived raw material dependency continues to present a significant challenge for the heparin market. Approximately 80% of active pharmaceutical ingredient volume originates in China, exposing international supply chains to animal disease outbreaks, tariffs, and geopolitical disruption. The African Swine Fever crisis from 2019 to 2021 demonstrated this vulnerability by tightening supplies and increasing costs.
Porcine mucosa represented 87.50% of global heparin market value in 2025 and remains central to production across China’s coastal manufacturing hubs. However, recombinant microbial sources are projected to grow at a CAGR of 9.10%, supported by private investment and public funding directed toward more resilient production systems.
Bovine-sourced heparin is also returning to regulated markets. In 2025, the U.S. Food and Drug Administration encouraged bovine sourcing as part of broader supply diversification efforts, supported by improved purification processes. The development of bovine, microbial, and biosynthetic alternatives could reduce dependence on porcine supply and limit future market volatility.
Key Heparin Market Drivers and Challenges
- Rising cardiovascular disease burden and an expanding aging population
- Increasing use of heparin in medical devices and surgical care
- Growth in dialysis procedures and outpatient anticoagulation
- Continued risk of adverse bleeding events
- Supply-chain exposure associated with animal-derived raw materials
Asia-Pacific Emerges as the Fastest-Growing Regional Market
Asia-Pacific generated 32.10% of global revenue in 2025 and is forecast to record the fastest regional CAGR of 8.19% from 2026 to 2031. China remains essential to global heparin processing, while policy initiatives increasingly emphasize research, development, manufacturing quality, and supply security. Programs in India and Southeast Asia designed to localize active pharmaceutical ingredient production may further expand regional capacity.
North America continues to record substantial demand due to high surgical volumes and a large chronic dialysis population. Regulatory support for diversified sourcing is expected to strengthen supply stability, although tariffs on Chinese imports and tighter controls for heparin testing systems may affect procurement and compliance strategies.
Europe maintains stable heparin consumption, supported by aging demographics and well-funded healthcare systems. Rigorous conformity assessments for drug-device combinations and regional approval requirements will continue to shape product development, launch schedules, and adoption of low-molecular-weight heparin products.
Overall, the global heparin market outlook remains positive as expanding clinical demand converges with innovation in biosynthetic manufacturing. Companies and healthcare systems that strengthen supply-chain resilience, improve product formats, and invest in non-animal production technologies are expected to be well positioned through 2031.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Escalating Surgical Procedure Volumes and Dialysis Procedures
4.2.2 Rapid Adoption of Low-Molecular-Weight Heparin Coupled with Expansion of Biosynthetic Heparin Programs
4.2.3 High Burden of Targeted Diseases and Ageing Population
4.2.4 Expanding Application in Medical Devices
4.2.5 Increasing Application in Oncology Care
4.2.6 Escalating Use of Heparin in Extracorporeal Membrane Oxygenation (ECMO) and Cardiopulmonary Bypass Circuits
4.3 Market Restraints
4.3.1 Supply-Chain Vulnerability due to Dependence on Animal Derived Raw Material
4.3.2 Risk and Adverse Bleeding Events
4.3.3 Stringent Regulatory Requirements
4.3.4 Therapeutic Shift Toward Direct Oral Anticoagulants in Long-term Thromboprophylaxis
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Outlook
4.6 Technological Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitute Products
4.7.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value in USD)
5.1 By Product
5.1.1 Unfractionated Heparin
5.1.2 Low-Molecular-Weight Heparin (LMWH)
5.1.3 Ultra-Low-Molecular-Weight Heparin (ULMWH)
5.1.4 Synthetic / Biosynthetic Heparin
5.2 By Source
5.2.1 Porcine
5.2.2 Bovine
5.2.3 Recombinant Microbial
5.3 By Dosage Form
5.3.1 Injectable Solution
5.3.2 Pre-filled Syringe
5.3.3 Topical Gel / Cream
5.3.4 Others
5.4 By Route of Administration
5.4.1 Intravenous
5.4.2 Sub-cutaneous
5.5 By Application
5.5.1 Deep Vein Thrombosis (DVT)
5.5.2 Atrial Fibrillation and Heart Attack
5.5.3 Coronary Artery Disease
5.5.4 Hemodialysis
5.5.5 Other Applications
5.6 By End User
5.6.1 Hospitals
5.6.2 Ambulatory Surgical Centers
5.6.3 Specialty Clinics
5.6.4 Home-care Settings
5.7 Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 South Korea
5.7.3.5 Australia
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East and Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East and Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
6.3.1 B. Braun Melsungen AG
6.3.2 Baxter International Inc.
6.3.3 Dr. Reddy’s Laboratories Ltd.
6.3.4 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
6.3.5 Leo Pharma A/S
6.3.6 Opocrin S.p.A.
6.3.7 Pfizer Inc.
6.3.8 Fresenius Kabi AG
6.3.9 Gland Pharma Ltd.
6.3.10 Hikma Pharmaceuticals PLC
6.3.11 Techdow Pharma USA Inc.
6.3.12 Viatris Inc.
6.3.13 Abbott
6.3.14 Smiths Medical (ICU Medical)
6.3.15 Sanofi S.A.
6.3.16 Shenzhen Hepalink Pharmaceutical Co. Ltd.
6.3.17 Bioiberica S.A.U.
6.3.18 Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd.
6.3.19 Cipla
6.3.20 Emcure Pharmaceuticals Ltd
7 Market Opportunities and Future Outlook
7.1 White-space and Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/ms22va
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Heparin Market Global Heparin Market Growth Rate By Region
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
